You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 300 No. 9, September 3, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (19)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Journalology/ Peer Review/ Authorship
 •Medical Practice
 •Academic Medical Centers
 •Conflict of Interest
 •Medical Education
 •Quality of Care
 •Quality of Care, Other
 •Statistics and Research Methods
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Industry-Sponsored Clinical Research

A Broken System

Marcia Angell, MD

JAMA. 2008;300(9):1069-1071.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Over the past 2 decades, the pharmaceutical industry has gained unprecedented control over the evaluation of its own products. Drug companies now finance most clinical research on prescription drugs, and there is mounting evidence that they often skew the research they sponsor to make their drugs look better and safer. Two recent articles underscore the problem: one showed that many publications concerning Merck's rofecoxib that were attributed primarily or solely to academic investigators were actually written by Merck employees or medical publishing companies hired by Merck1; the other showed that the company manipulated the data analysis in 2 clinical trials to minimize the increased mortality associated with rofecoxib.2 Bias in the way industry-sponsored research is conducted and reported is not unusual and by no means limited to Merck.3

The problem is not so much the sponsorship itself but the terms. Before the 1980s, industry grants to . . . [Full Text of this Article]

Author Affiliation: Department of Global Health and Social Medicine, Harvard Medical School, Cambridge, Massachusetts.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

Low-Carbohydrate Diet and Blood Lipid Levels: How Good and How Fast?
Dario Giugliano, Maria Ida Maiorino, and Katherine Esposito
Arch Intern Med. 2009;169(20):1930.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low-Carbohydrate Diet and Blood Lipid Levels: How Good and How Fast?
Giugliano et al.
Arch Intern Med 2009;169:1930-1930.
FULL TEXT  

Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Trial
Esposito et al.
ANN INTERN MED 2009;151:306-314.
ABSTRACT | FULL TEXT  

The Role of Conflict of Interest in Reporting of Scientific Information
Irwin
Chest 2009;136:253-259.
ABSTRACT | FULL TEXT  

Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals
Mello et al.
NEJM 2009;360:1557-1566.
FULL TEXT  

PERIODONTAL DISEASE AND OTHER DISEASES
Pallasch
Journal of the American Dental Association 2009;140:16-17.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.